6ruu: Difference between revisions
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
<StructureSection load='6ruu' size='340' side='right'caption='[[6ruu]], [[Resolution|resolution]] 2.95Å' scene=''> | <StructureSection load='6ruu' size='340' side='right'caption='[[6ruu]], [[Resolution|resolution]] 2.95Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[6ruu]] is a 3 chain structure with sequence from [https://en.wikipedia.org/wiki/ | <table><tr><td colspan='2'>[[6ruu]] is a 3 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6RUU OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6RUU FirstGlance]. <br> | ||
</td></tr><tr id=' | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.95Å</td></tr> | ||
<tr id=' | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=HG:MERCURY+(II)+ION'>HG</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr> | ||
< | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6ruu FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6ruu OCA], [https://pdbe.org/6ruu PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6ruu RCSB], [https://www.ebi.ac.uk/pdbsum/6ruu PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6ruu ProSAT]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6ruu FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6ruu OCA], [https://pdbe.org/6ruu PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6ruu RCSB], [https://www.ebi.ac.uk/pdbsum/6ruu PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6ruu ProSAT]</span></td></tr> | ||
</table> | </table> | ||
== Disease == | == Disease == | ||
[https://www.uniprot.org/uniprot/IRAK3_HUMAN IRAK3_HUMAN] Disease susceptibility is associated with variations affecting the gene represented in this entry. | |||
== Function == | == Function == | ||
[https://www.uniprot.org/uniprot/IRAK3_HUMAN IRAK3_HUMAN] Inhibits dissociation of IRAK1 and IRAK4 from the Toll-like receptor signaling complex by either inhibiting the phosphorylation of IRAK1 and IRAK4 or stabilizing the receptor complex.[UniProtKB:Q8K4B2]<ref>PMID:10383454</ref> | |||
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
== Publication Abstract from PubMed == | == Publication Abstract from PubMed == | ||
| Line 22: | Line 21: | ||
</div> | </div> | ||
<div class="pdbe-citations 6ruu" style="background-color:#fffaf0;"></div> | <div class="pdbe-citations 6ruu" style="background-color:#fffaf0;"></div> | ||
==See Also== | |||
*[[Interleukin-1 receptor-associated kinase|Interleukin-1 receptor-associated kinase]] | |||
== References == | == References == | ||
<references/> | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: | [[Category: Homo sapiens]] | ||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
[[Category: Cohen P]] | |||
[[Category: Cohen | [[Category: Kulathu Y]] | ||
[[Category: Kulathu | [[Category: Lange SM]] | ||
[[Category: Lange | |||
Revision as of 15:29, 24 January 2024
Pseudokinase domain of human IRAK3Pseudokinase domain of human IRAK3
Structural highlights
DiseaseIRAK3_HUMAN Disease susceptibility is associated with variations affecting the gene represented in this entry. FunctionIRAK3_HUMAN Inhibits dissociation of IRAK1 and IRAK4 from the Toll-like receptor signaling complex by either inhibiting the phosphorylation of IRAK1 and IRAK4 or stabilizing the receptor complex.[UniProtKB:Q8K4B2][1] Publication Abstract from PubMedInterleukin-1 receptor associated kinases (IRAKs) are key players in innate immune signaling that mediate the host response to pathogens. In contrast to the active kinases IRAK1 and IRAK4, IRAK2 and IRAK3 are pseudokinases lacking catalytic activity and their functions are poorly understood. IRAK3 is thought to be a negative regulator of innate immune signaling and mutations in IRAK3 are associated with asthma and cancer. Here, we report the crystal structure of the human IRAK3 pseudokinase domain in a closed, pseudoactive conformation. IRAK3 dimerizes in a unique way through a head-to-head arrangement not observed in any other kinases. Multiple conserved cysteine residues imply a potential redox control of IRAK3 conformation and dimerization. By analyzing asthma-associated mutations, we identify an evolutionarily conserved surface on IRAK3 that could form an interaction interface with IRAK4, suggesting a model for the negative regulation of IRAK4 by IRAK3. Dimeric Structure of the Pseudokinase IRAK3 Suggests an Allosteric Mechanism for Negative Regulation.,Lange SM, Nelen MI, Cohen P, Kulathu Y Structure. 2020 Nov 17. pii: S0969-2126(20)30416-0. doi:, 10.1016/j.str.2020.11.004. PMID:33238146[2] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
| ||||||||||||||||||